Smedvig leads $13.5m investment in TrialReach

Other participants in the funding round include Amadeus Capital Partners and Octopus Investments.

The fresh funding will be used to support the company's expansion into the US.

Company
Established in 2010, TrialReach connects patients with clinical trials. According to the company, one in five cancer trials in the US fails to find participants and just 3% of adult patients take part in cancer research.

TrialReach operates through a platform that aggregates and structures all clinical trial listings worldwide, so patients can be matched with relevant trials.

The company works with health organisations including the World Health Organization, as well as pharmaceutical businesses. To reach patients, TrialReach has online partnerships with health portals including Healthline, Everyday Health and CenterWatch.

People
Pablo Gravier is CEO of TrialReach. Jordan Mayo is managing director of Smedvig.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• Smedvig Capital
• Octopus Investments
• Amadeus Capital